[1] ISLAM M A,KHANDKER S S,KOTYLA P J,et al.Immunomodulatory effects of diet and nutrients in systemic lupus erythematosus(SLE):A systematic review[J].Front Immunol,2020(11):1477. [2] 郭雪婷,秦文娟,黄磊,等.三维斑点追踪技术评价系统性红斑狼疮患者左心室收缩功能及舒张功能[J].广州医药,2020,51(2):58-93. [3] 谷晓晶,范斌,李荣平,等.应用3.0 磁共振成像评价儿童系统性红斑狼疮脑损伤的临床研究[J].现代医院,2020,20(11):1710-1712. [4] DURCAN L,O’DWYER T,PETRI M.Management strategies and future directions for systemic lupus erythematosus in adults[J].Lancet,2019,393(10188):2332-2343. [5] KIRIAKIDOU M,CHING C L.Systemic lupus erythematosus[J].Ann Intern Med,2020,172(11):ITC81-ITC96. [6] PAWELEC P,ZIEMKA-NALECZ M,SYPECKA J,et al.The impact of the CX3CL1/CX3CR1 axis in neurological disorders[J].Cells,2020,9(10):2277. [7] SUBBARAYAN M S,JOLY-AMADO A,BICKFORD PC,et al.CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases[J].Pharmacol Ther,2022(231):107989. [8] HELMKE A,NORDLOHNE J,BALZER M S,et al.CX3CL1-CX3CR1 interaction mediates macrophage-mesothelial cross talk and promotes peritoneal fibrosis[J].Kidney Int,2019,95(6):1405-1417. [9] NI Y,ZHUGE F,NI L,et al.CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status[J].Metabolism,2022(136):155272. [10] LU X.Structure and function of ligand CX3CL1 and its receptor CX3CR1 in cancer[J].Curr Med Chem,2022,29(41):6228-6246. [11] ZHUANG Q,CHENG K,MING Y.CX3CL1/CX3CR1 axis,as the therapeutic potential in renal diseases:Friend or foe?[J].Curr Gene Ther,2017,17(6):442-452. [12] FENG X,ZHU S,QIAO J,et al.CX3CL1 promotes M1 macrophage polarization and osteoclast differentiation through NF-κB signaling pathway in ankylosing spondylitis in vitro[J].J Transl Med,2023,21(1):573. [13] TANG J,LIAO Z,LUO L,et al.CX3CL1-induced CD16+ monocytes extravasation in myeloperoxidase-ANCA-associated vasculitis correlates with renal damage[J].Front Immunol,2022(13):929244. [14] APOSTOLAKIS S,SPANDIDOS D.Chemokines and atherosclerosis:Focus on the CX3CL1/CX3CR1 pathway[J].Acta Pharmacol Sin,2013,34(10):1251-1256. [15] RIOPEL M,VASSALLO M,EHINGER E,et al.CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice[J].Mol Metab,2019(20):89-101. [16] LIU W,JIANG L,BIAN C,et al.Role of CX3CL1 in diseases[J].Arch Immunol Ther Exp,2016,64(5):371-383. [17] INOUE A,HASEGAWA H,KOHNO M,et al.Antagonist of fractalkine(CX3CL1)delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice[J].Arthritis Rheum,2005,52(5):1522-1533. [18] 李遇梅,姚煦,陈敏,等.系统性红斑狼疮患者外周血单一核细胞CX3CR1趋化因子受体mRNA的表达[J].江苏大学学报(医学版),2009,19(1):10-13. [19] SEKULA P,DEL GRECO M F,PATTARO C,et al.Mendelian randomization as an approach to assess causality using observational data[J].J Am Soc Nephrol,2016,27(11):3253-3265. [20] DAVEY SMITH G,HEMANI G.Mendelian randomization:Genetic anchors for causal inference in epidemiological studies[J].Hum Mol Genet,2014,23(R1):R89-98. [21] BURGESS S,BUTTERWORTH A,THOMPSON SG.Mendelian randomization analysis with multiple genetic variants using summarized data[J].Genet Epidemiol,2013,37(7):658-665. [22] BURGESS S,THOMPSON S G.Interpreting findings from Mendelian randomization using the MR-Egger method[J].Eur J Epidemiol,2017,32(5):377-389. [23] BOWDEN J,DAVEY SMITH G,HAYCOCK P C,et al.Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator[J].Genet Epidemiol,2016,40(4):304-314. [24] HARTWIG F P,DAVEY SMITH G,BOWDEN J.Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption[J].Int J Epidemiol,2017,46(6):1985-1998. [25] GRECO M F,MINELLI C,SHEEHAN N A,et al.Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome[J].Stat Med,2015,34(21):2926-2940. [26] BOWDEN J,DAVEY SMITH G,BURGESS S.Mendelian randomization with invalid instruments:Effect estimation and bias detection through Egger regression[J].Int J Epidemiol,2015,44(2):512-525. [27] VERBANCK M,CHEN C Y,NEALE B,et al.Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases[J].Nat Genet,2018,50(5):693-698. [28] QIU F,LI Y,ZHU Y,et al.CX3CR1 might be a promising predictor of systemic lupus erythematosus patients with pulmonary fibrosis[J].Scand J Immunol,2021,94(1):e13038. [29] STAUMONT-SALL D,FLEURY S,LAZZARI A,et al.CX3 CL1(fractalkine)and its receptor CX3 CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin[J].J Exp Med,2014,211(6):1185-1196. [30] von VIETINGHOFF S,KURTS C.Regulation and function of CX3CR1 and its ligand CX3CL1 in kidney disease[J].Cell Tissue Res,2021,385(2):335-344. [31] PLANT D,YOUNG H S,WATSON R E,et al.The CX3CL1-CX3CR1 system and psoriasis[J].Exp Dermatol,2006,15(11):900-903. [32] ZHANG C,ZHANG Y,ZHUANG R,et al.Alterations in CX3CL1 levels and its role in viral pathogenesis[J].Int J Mol Sci,2024 25(8):44518. [33] SALNIKOVA D I,NIKIFOROV N G,POSTNOV A Y,et al.Target role of monocytes as key cells of innate immunity in rheumatoid arthritis[J].Diseases,2024,12(5):81. [34] SZUKIEWICZ D.CX3CL1(fractalkine)-CX3CR1 axis in inflammation-induced angiogenesis and tumorigenesis[J].Int J Mol Sci,2024,25(9):4679. [35] 次旦朗杰,孙晓景,次仁德吉.CX3CL1-CX3CR1轴在类风湿性关节炎中的作用[J].西藏医药,2024,45(3):145-147. [36] ESTALEEN R A,REILLY C M,LUO X M.A double-edged sword:Interactions of CX3CL1/CX3CR1 and gut microbiota in systemic lupus erythematosus[J].Front Immunol,2024(14):1330500. [37] MELAMUD M M,ERMAKOV E A.Multiplex analysis of serum cytokine profiles in systemic lupus erythematosus and multiple sclerosis[J].Int J Mol Sci,2022,23(22):13829. |